Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

How to Use Peptides for Addiction Recovery: Protocol Comparison

The table below compares the three most researched peptides for addiction recovery based on mechanism, dosing structure, clinical evidence quality, and realistic outcome expectations. Cerebrolysin BDNF/NGF-mediated synaptogenesis in reward pathways 10–30ml IM,

This comparison does not assign a generated winner or score.

  • The table below compares the three most researched peptides for addiction recovery based on mechanism, dosing structure, clinical evidence quality, and realistic outcome expectations.
  • Cerebrolysin
  • BDNF/NGF-mediated synaptogenesis in reward pathways
  • 10–30ml IM, 3× weekly, 4–6 week cycles
  • Moderate. RCTs in methamphetamine and alcohol dependence
  • Craving reduction noticeable by week 3–4; measurable receptor upregulation by week 6–8
  • Best-supported compound for stimulant and alcohol addiction; requires IM administration
  • Dihexa
  • HGF receptor activation. Synaptic density amplification
  • 1–3mg SubQ daily, 8–12 week cycles
  • Low. Animal models only; no Phase III human addiction trials
  • Cognitive clarity improvement by week 4–5; neuroplasticity gains slower than Cerebrolysin
  • Promising for dopamine pathway repair but lacks direct addiction-focused clinical validation
  • Thymalin
  • Thymic peptide. Immune normalization, reduces neuroinflammation
  • 10mg SubQ daily × 10 days, then 3–4 month rest
  • Low. Primarily studied for immune senescence, not addiction
  • Inflammation markers reduce by day 7–10; indirect neuroplasticity support only
  • Adjunct compound. Addresses inflammatory barrier to recovery but not a standalone solution
More references

Related material